Mitsunori Morita

Akashi, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Efficacy of S-1 Monotherapy for Salivary Duct Carcinoma With MYC Amplification.

Efficacy of S-1 Monotherapy for Salivary Duct Carcinoma With MYC Amplification.

Journal: In vivo (Athens, Greece)
Published: April 03, 2026

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).

Journal: Breast cancer research and treatment
Published: March 30, 2026

Optimal Sunitinib Dosing Based on Platelet Count in an Older Patient With Gastrointestinal Stromal Tumor.

Optimal Sunitinib Dosing Based on Platelet Count in an Older Patient With Gastrointestinal Stromal Tumor.

Journal: In vivo (Athens, Greece)
Published: September 01, 2025

Low-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With KIT Exon 11 W557_K558 Deletion.

Low-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With KIT Exon 11 W557_K558 Deletion.

Journal: In vivo (Athens, Greece)
Published: October 10, 2024

Current status of carboplatin desensitization therapy for gynecologic malignancies.

Current status of carboplatin desensitization therapy for gynecologic malignancies.

Journal: Journal of gynecologic oncology
Published: September 15, 2024

A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.

A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.

Journal: Cancer medicine
Published: October 17, 2023

Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

Journal: Investigational new drugs
Published: November 20, 2021

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.

Journal: BMC cancer
Published: November 11, 2020

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

Journal: Investigational new drugs
Published: November 15, 2019

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.

Journal: BMC cancer
Published: September 29, 2019

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Journal: Clinical lung cancer
Published: August 26, 2019

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

Journal: Investigational new drugs
Published: July 22, 2019
Showing 1-12 of 22

Last Updated: 09/26/2026